3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
17
Terminated
3
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Gastrointestinal Stromal Tumors
8
Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
2
Hematologic Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Rare Tumor
1
Rare Malignant Neoplasm
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Chronic-Phase
1
Digestive System Neoplasms
1
Congenital Bone Marrow Failure Syndromes
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
Cytarabine
3
ponatinib
2
blinatumomab
2
Idarubicin
2
Cladribine
2
venetoclax
1
nilotinib
1
midostaurin
1
merphos
1
gilteritinib
1
fludarabine
1
bosutinib
1
asciminib
1
Succimer
1
Specimen Handling
1
Razoxane
1
Positron-Emission Tomography
1
Pentetic Acid
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Imatinib Mesylate
1
Geritol
1
Gemtuzumab
1
Edetic Acid
1
Dexrazoxane
1
Dasatinib
1
Cyclophosphamide
1
Blood Component Removal
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Blast Crisis
×
Imatinib Mesylate
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled